Valuation dashboard for Oramed Pharmaceuticals Inc. (ORMP) with P/E 1.09, P/B 0.60, EV/EBITDA 1.26 and dividend yield 5.41%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes.
Analysis Summary
Oramed Pharmaceuticals Inc. reported revenue of $2.0M in the most recent fiscal year, growing at a 5-year CAGR of -5.9%.
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $4.62, ORMP trades at a P/E of 1.09 and an ROE of 72.96%. Market capitalisation stands at $189M.
Balance sheet quality for ORMP: current ratio of 7.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 1.09 |
| Price / Book | 0.60 |
| EV / EBITDA | 1.26 |
| Dividend Yield | 5.41% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ORMP | Oramed Pharmaceuticals Inc. | $189M | 1.09 | 0.60 | 73.0% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $4.62 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 72.96% |
| Return on Invested Capital | -3.21% |
| Return on Assets | 47.31% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLNN · CNTB · CNTX · COYA · IFRX · IMA · KLRS
Explore sector: Healthcare · Biotechnology
More sections of ORMP: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks